​

Funding Round

Series A - Werewolf Therapeutics

Series A - Werewolf Therapeutics

Investment Firm

Overview

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Announced Date

Nov 20, 2019

Closed on Date

Nov 20, 2019

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

MPM Capital

MPM Capital

MPM Capital is a early_stage_venture and late_stage_venture and private_equity and seed firm.

Longwood Fund

Longwood Fund

Longwood Fund is a early_stage_venture and late_stage_venture and private_equity and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorDC Capital Partners
Participant InvestorUPMC
Participant InvestorLongwood Fund
Participant InvestorMPM Capital
Participant InvestorTaiho Ventures

Round Details and Background

Werewolf Therapeutics raised $56172597 on 2019-11-20 in Series A

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 20, 2019
Series A - Werewolf Therapeutics
6-56.2M
Jan 07, 2021
Series B - Werewolf Therapeutics
13-72.0M
May 10, 2022
Post-IPO Secondary - Werewolf Therapeutics
-50.0M

Recent Activity

There is no recent news or activity for this profile.